CL2008002853A1 - Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02) - Google Patents

Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02)

Info

Publication number
CL2008002853A1
CL2008002853A1 CL2008002853A CL2008002853A CL2008002853A1 CL 2008002853 A1 CL2008002853 A1 CL 2008002853A1 CL 2008002853 A CL2008002853 A CL 2008002853A CL 2008002853 A CL2008002853 A CL 2008002853A CL 2008002853 A1 CL2008002853 A1 CL 2008002853A1
Authority
CL
Chile
Prior art keywords
mif
angiogenesis
quinoline
arthritis
inflammation
Prior art date
Application number
CL2008002853A
Other languages
Spanish (es)
Inventor
Kumar K C Sunil
C A Gaeta Federico
Baird Andrew
Anchin Jerry
Ying Wenbin
Florkiewicz Robert
Sircar Jagadish
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51399105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of CL2008002853A1 publication Critical patent/CL2008002853A1/en

Links

Abstract

Compuestos derivados de piraziin-quinolina sustituida, inhibidores de la migración de macrófagos (MIF); procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de inflamación, shock séptico, artritis, cáncer, trastornos autoinmunes e inhibición de angiogénesis.Compounds derived from substituted piraziin-quinoline, macrophage migration (MIF) inhibitors; preparation procedure; pharmaceutical composition; and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis.

CL2008002853A 2002-05-24 2008-09-25 Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02) CL2008002853A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29364202P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
CL2008002853A1 true CL2008002853A1 (en) 2008-12-26

Family

ID=51399105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002853A CL2008002853A1 (en) 2002-05-24 2008-09-25 Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02)

Country Status (1)

Country Link
CL (1) CL2008002853A1 (en)

Similar Documents

Publication Publication Date Title
WO2004020599A3 (en) Hedgehog antagonists, methods and uses related thereto
BRPI0418112A (en) heterocyclic bicyclic p-38 kinase inhibitors
SG146624A1 (en) Cytokine inhibitors
CL2003002353A1 (en) COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
HRP941000B9 (en) Morpholine and thiomorpholine tachykinin receptor antagonists
DE69732868D1 (en) Remedy for itching
ATE304355T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITING THE PRODUCTION AND SECRETION OF CYTOKINES
CY1106357T1 (en) ADAMANTANIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY, IMMUNE AND CARDIOVASCULAR DISEASES
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
DK1420801T3 (en) Use of fucans for the treatment of adhesions, arthritis and psoreasis
NO20032254D0 (en) Compounds for inhibiting expression of VACM-I
DE69824037D1 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
DE60142921D1 (en) AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS
DE60118003D1 (en) UREA DERIVATIVES AND ITS USE
MXPA04002070A (en) Substituted indazole compounds for the treatment of inflammation.
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
ATE231872T1 (en) THIAZOLOPYRIMIDE DERIVATIVES
DE60324544D1 (en) MUSCARIN ANTAGONISTS
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
BRPI0515721A (en) use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
DE69919179D1 (en) SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONE AND THEIR ANALOGS, AND THEIR USE
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
EA200200545A1 (en) ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
MEP16208A (en) A combination comprising combretastatin and anticancer agents